Artificial intelligence continues to transform biotechnology with novel tools facilitating gene editing and biomedical analyses. Researchers have developed CRISPR-GPT, an AI system leveraging large language models to automate gene-editing experiment design and analysis across novice to expert levels, democratizing access to genetic engineering. Similarly, Profluent's AI-designed programmable gene editors have demonstrated improved activity and specificity compared to natural counterparts. Additionally, Stanford and Chan Zuckerberg Biohub unveiled a Virtual Lab system of AI agents capable of conducting interdisciplinary scientific research autonomously, accelerating pathogen-targeting nanobody discovery. These innovations are poised to shift paradigms in biomedicine and accelerate therapeutic development.